Varicella Clinical Trial
Official title:
Assessment of the Memory Immune Response, Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV and Long-Term Follow-Up
Verified date | March 2022 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in participants previously vaccinated with JE-CV vaccine. Objectives: - To describe JE immune status before and after JE-CV vaccination in subjects previously vaccinated with JE-CV vaccine - To describe the immune status before and after JE-CV vaccination in JE-naïve control subjects. - To describe the safety (in terms of solicited and unsolicited adverse events) of a single dose of JE-CV vaccine up to 6 months after the last vaccination. - To describe all related serious adverse events (SAEs) and related deaths from 6 months to 5 years after vaccination in JE-CV-primed subjects.
Status | Completed |
Enrollment | 454 |
Est. completion date | October 12, 2015 |
Est. primary completion date | October 29, 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 36 Months to 42 Months |
Eligibility | An individual had to fulfill all of the following criteria in order to be eligible for trial enrollment: All Participants - Aged 36 to 42 months on the day of inclusion - Provision of Informed Consent Form signed by at least one parent or other legally acceptable representative - Participant and parent/legally acceptable representative or guardian able to attend all scheduled visits and to comply with all trial procedures - In good general health, based on medical history and physical examination For JE-CV vaccine primed group only - Participant who was vaccinated with JE-CV in JEC02 trial (NCT00735644) An individual fulfilling any of the following criteria was excluded from trial enrollment: All Participants - Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination - Planned participation in another clinical trial during the Day 0 - Month 6 period and for Group 1 up to 5 years for any flavivirus vaccine trial - Receipt of any vaccine* in the 4 weeks preceding the trial vaccination, except for pandemic influenza vaccination, which may be received at least 2 weeks before study vaccines - Planned receipt of any vaccine* in the 4 weeks following the trial vaccination, except for pandemic influenza vaccine. In the event of local or national immunization program with a pandemic influenza vaccine, participants who receive a pandemic influenza vaccine at any time during the trial will not be withdrawn from the trial. - Planned receipt of any JE vaccine during the course of the trial - Administration of any anti-viral within 2 months preceding the trial vaccination and up to 4 weeks following the trial vaccination - Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response - Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) - Seropositivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, as reported by the parent/legally acceptable representative - History of central nervous system disorder or disease, including seizures and febrile seizures - Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances - Chronic illness or any underlying illness (such as cardiovascular, kidney, liver or hematological disease or development abnormalities) that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion - Except in case of national immunization days with oral polio vaccine For JE-CV primed participants only - Receipt of any JE vaccine other than JE-CV during JEC02 trial(NCT00735644) and since the end of JEC02 trial For JE-CV naïve participants only - Previous vaccination against flavivirus disease including JE - History of flavivirus infection either based on clinical suspicion or laboratory proven - Previous vaccination against varicella - Previous vaccination with JE-CV in JEC02 study - History of varicella, confirmed either clinically, serologically, or microbiologically - Known systemic hypersensitivity or anaphylactic/anaphylactoid reaction to neomycin. - Known history of thrombocytopenia or idiopathic thrombocytopenic purpura Temporary Contraindications: A prospective participant was not to be included in the study until the following conditions and/or symptoms had resolved: 1. Receipt of oral or injected antibiotic therapy within 72 hours prior to the first blood draw (for Groups 1 and 2) 2. Febrile illness (temperature =38.0°C [=100.4°F]) or moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination (for all participants) The Investigator was to postpone vaccination until the situation/condition resolved. Vaccination could be postponed within the timeframe for vaccination indicated in the protocol trial flowchart. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sanofi Pasteur, a Sanofi Company |
Philippines,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With JE Seroprotection Before and Following a Dose of Live Attenuated JE-CV | The presence of JE virus neutralizing antibodies was measured using a 50% plaque reduction neutralization test (PRNT50). Seroprotection status for antibody levels against JE virus before (on Day 0) and after JE-CV vaccination (Day 7 and Day 28) was defined as neutralizing antibody titer = 10 (1/dilution). | Day 0 (pre-vaccination) and Day 7 and Day 28 post-vaccination | |
Primary | Percentage of Participants With JE Seroconversion Following a Dose of Live Attenuated JE-CV Vaccine | The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. Seroconversion was defined as participants with a pre-vaccination titer <10 (1/dilution) and post-vaccination titer =10 (1/dilution, or participants with pre vaccination titer =10 (1/dilution) and a =4-fold increase from pre- to post-vaccination. | Day 0 (pre-vaccination) and Day 7 and Day 28 post-vaccination | |
Primary | Summary of Geometric Mean Titers of JE Virus Antibodies Following a Dose of Live Attenuated JE-CV | The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. | Day 0 (pre-vaccination) and Day 7 and Day 28 post-vaccination | |
Primary | Summary of Geometric Mean Titer Ratios of JE Virus Antibodies Following a Dose of Live Attenuated JE-CV | The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. | Day 0 (pre-vaccination) and Day 7 and Day 28 post-vaccination | |
Primary | Summary of Serological Flavivirus Status at Baseline of Participants Vaccinated With a Dose of Live Attenuated JE-CV | The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. Flavivirus positive was defined as titers against JE virus =10 (1/dilution) or titers against at least 1 dengue serotype =10 (1/dilution). Flavivirus negative was defined as titers against JE virus <10 (1/dilution) and titers against the 4 dengue serotypes <10 (1/dilution). | Day 0 (pre-vaccination) | |
Primary | Percentage of Participants With JE Seroprotection Before and Up to 5 Years Following a Booster Dose of Live Attenuated JE-CV | The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. Seroprotection status for antibody levels against JE virus before (on Day 0) and after JE-CV vaccination (Days 7 and 28 and Years 1, 2, 3, 4, and 5) was defined as neutralizing antibody titer = 10 (1/dilution). | Day 0 (pre-vaccination) and Days 7 and 28, and Year 1, 2, 3, 4, and 5 post-vaccination | |
Primary | Summary of Geometric Mean Titer of JE Virus Antibodies Before and Up to 5 Years Following a Booster Dose of Live Attenuated JE-CV | The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. | Day 0 (pre-vaccination) and Days 7 and 28 and Year 1, 2, 3, 4, and 5 post-vaccination | |
Primary | Summary of Geometric Mean Titer Ratios of JE Virus Antibodies Up to 5 Years Following a Booster Dose of Live Attenuated JE-CV | The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. | Year 1, 2, 3, 4, and 5 post-vaccination | |
Primary | Number of Participants With Solicited Injection-Site Reactions and Systemic Reactions Following a Dose of Live Attenuated JE-CV or Varicella Vaccine | Injection-site reactions: Pain, Erythema, and Swelling. Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3 Injection-site reactions: Pain, Incapacitating, unable to perform usual activities. Erythema and Swelling, =5 cm. Grade 3 Systemic reactions: Fever, 39.0°C; Headache, Malaise, and Myalgia, Significant; prevents daily activities. | Day 0 up to Day 14 post-vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00792623 -
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).
|
Phase 2 | |
Enrolling by invitation |
NCT05015686 -
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
|
Phase 3 | |
Completed |
NCT00092430 -
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
|
Phase 3 | |
Completed |
NCT00384397 -
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT00226499 -
Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox
|
Phase 3 | |
Completed |
NCT00402831 -
ProQuad® Intramuscular vs Subcutaneous
|
Phase 3 | |
Not yet recruiting |
NCT06068608 -
A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy
|
Phase 1 | |
Completed |
NCT00560755 -
Safety Study of ProQuad® rHA in Infants (V221-037)
|
Phase 3 | |
Completed |
NCT00715234 -
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
|
N/A | |
Terminated |
NCT00258726 -
Immune Responses to Two Dose Varivax +/- MMR-II
|
Phase 1/Phase 2 | |
Completed |
NCT03239873 -
Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
|
Phase 3 | |
Completed |
NCT00751348 -
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
|
Phase 3 | |
Completed |
NCT00969436 -
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
|
Phase 3 | |
Completed |
NCT00566527 -
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
|
Phase 3 | |
Completed |
NCT01390857 -
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
|
N/A | |
Completed |
NCT00127010 -
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
|
Phase 3 | |
Completed |
NCT00578175 -
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
|
Phase 2 | |
Completed |
NCT00568334 -
Study of Two Formulations of GSK Biologicals' Varicella Vaccine
|
Phase 2 | |
Completed |
NCT03114982 -
The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age
|
Phase 2 | |
Completed |
NCT00483574 -
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
|
Phase 3 |